Dr. Hochster on Take-Home Message of the POLO Trial in Pancreatic Cancer

Dr. Macarulla Discusses Rapid Progressors in the POLO Trial in Pancreatic CancerПодробнее

Dr. Hall Discusses Rationale for the POLO Trial in Metastatic Pancreatic CancerПодробнее

Philip Philip MD, PhD, FRCP, discusses outcomes from the POLO trial in pancreatic cancerПодробнее

Comment: POLO III trial for metastatic pancreatic cancerПодробнее

Olaparib in metastatic pancreatic cancer, the POLO trialПодробнее

POLO: Olaparib as maintenance treatment for metastatic pancreatic cancerПодробнее

Dr. Richards on Secondary Endpoints of the POLO Trial in Pancreatic CancerПодробнее

POLO Trial in Pancreatic CancerПодробнее

Dr. Richards on the Phase III POLO Trial in BRCA-Mutated Pancreatic CancerПодробнее

POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients wi...Подробнее

Dr. Bekaii-Saab on the APACT Trial in Pancreatic CancerПодробнее

POLO: maintenance olaparib in BRCA1/2 metastatic pancreatic cancerПодробнее

PARP Inhibitors gBRCA1/2-Mutated Pancreatic CancerПодробнее

Dr. Golan on the Phase III POLO Trial in BRCA-Mutant Pancreatic CancerПодробнее

Dr. O’Reilly on Investigational Treatment Approaches in Pancreatic CancerПодробнее

Dr Reber Speaks on Surgical Strategies in Pancreatic CancerПодробнее

Journal Club POLO trial Pancreatic Cancer 05 03 2022Подробнее

Dr. Hochster on Results from the SWOG S1513 Study for Pancreatic CancerПодробнее

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutationsПодробнее